deucrictibant

Phase 3Small molecule

PPharvaris Netherlands B.V.

deucrictibant is one of 22 small molecule programs targeting Hereditary Angioedema (HAE). It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hereditary Angioedema (HAE)Recruiting

AngioedemaRecruiting

Hereditary AngioedemaEnrolling by invitation

Hereditary Angioedema (HAE)Phase 3

Recruiting

AngioedemaPhase 3

Recruiting

Hereditary AngioedemaPhase 3

Enrolling by invitation

Competition

Competitive Landscape

13 competitors in Hereditary Angioedema

#DrugCompanyPhaseTrials

Crestor

Neoral

Lanoxin

Andembry

1 5

Dawnzera (autoinjector)

Ionis Pharmaceuticals

Phase 3

5 6

Orladeyo

BBioCryst Pharmaceuticals

Phase 3

1 7

deucrictibant

PPharvaris Netherlands B.V.

Phase 3

4 8

KVD900

KKalVista Pharmaceuticals, Ltd.

Phase 3

5 9

ADX-324

AADARx Pharmaceuticals, Inc.

Phase 2

2 10

Heparin Sodium

BBaxter Healthcare Corporation

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Recruiting

Angioedema

NCT07266805

Q4 2028

Phase 3Recruiting

Hereditary Angioedema (HAE)

NCT06679881

Clinical

Trials by Indication[1]

Hereditary Angioedema4 trials

Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

Completed·PPharvaris Netherlands B.V.·Phase 2·NCT04618211·74 enrolled

Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients

Recruiting·IInstitute for Asthma and Allergy·Phase 1/2·NCT07046806·10 enrolled

A Phase II, Double-blind, Placebo-controlled, Randomized, Dose-ranging, Parallel Group Study to Evaluate the Safety and Efficacy of PHA-022121 Administered Orally for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Due to C1-Inhibitor Deficiency (Type I or Type II)

Terminated·PPharvaris Netherlands B.V.·Phase 2·NCT05047185·34 enrolled

Show 1 more trial

A Phase II/III, Extension Study of Orally Administered PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

Enrolling by invitation·PPharvaris Netherlands B.V.·Preclinical·NCT05396105·150 enrolled

Angioedema2 trials

Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

Active, not recruiting·PPharvaris Netherlands B.V.·Phase 3·NCT06669754·81 enrolled

A Phase 3, Randomized, Double-blind, Placebo-controlled, 3-Part Study to Evaluate the Efficacy and Safety of Orally Administered Deucrictibant Extended-release (XR) Tablet for Prophylaxis and Deucrictibant Immediate-release (IR) Capsule for On-demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency

Recruiting·PPharvaris Netherlands B.V.·Phase 3·NCT07266805·32 enrolled

Hereditary Angioedema (HAE)1 trial

A Long-term, Open-label Study to Evaluate the Safety and Efficacy of Orally Administered Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

Recruiting·PPharvaris Netherlands B.V.·Phase 3·NCT06679881·170 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for deucrictibant. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — deucrictibant compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for deucrictibant. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pharvaris Netherlands B.V. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: PPharvaris Netherlands B.V.

deucrictibant

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2028

Trials by Indication[1]

Hereditary Angioedema4 trials

Angioedema2 trials

Hereditary Angioedema (HAE)1 trial

References

Drug Info

Quick Facts

Related News